Navigation Links
Onyx Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Date:2/2/2010

EMERYVILLE, Calif., Feb. 2 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the 12th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2010 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time).  Interested parties may access a live webcast of the presentation on our website at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through February 23, 2010.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation pro
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Onyx Pharmaceuticals Appoints Ted W. Love, M.D., as Head of Research & Development
2. Eribis Pharmaceuticals Receives Investment for Clinical Development of Novel Cardiovascular Therapy
3. China Yongxin Pharmaceuticals Plans to Open Eighteen New Stores in 2010 to Further Expand Customer Base and Increase Market Share
4. Poniard Pharmaceuticals, Inc. to Present Additional Cancer Treatment Data Found Significant by TapeBeat.Com Investors
5. Peregrine Pharmaceuticals Appoints Dr. Marvin R. Garovoy as Head of Clinical Science
6. Amira Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. China Yongxin Pharmaceuticals Opened Three New Stores in 2009 and Expanded Customer Base
8. China Yongxin Pharmaceuticals Projects Higher Net Income and EPS on Reduced Revenue for Full-Year 2009
9. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
10. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
11. Poniard Pharmaceuticals Announces $6.5 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... May 06, 2015 Histogen, Inc., ... the products of cells grown under simulated embryonic ... immunomodulatory treatment candidate for melanoma during the 2015 ... place May 6-9, 2015 in Atlanta, GA. , ... produce a soluble material with anti-oncologic properties, with ...
(Date:5/5/2015)... , May 5, 2015  Blueprint Medicines (NASDAQ: ... its initial public offering of 9,367,708 shares of ... $18.00 per share, including shares of common stock ... of their option to purchase additional shares. The ... Blueprint Medicines were approximately $168.6 million, before underwriting discounts ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 VetStem ... Science Animal Health, Jeffrey Schaffer, DVM, as Director ... over 15 years of experience in the veterinary ... great addition to our veterinarian lead organization”. ... explains. “Dr. Schaffer will be responsible for all ...
(Date:5/5/2015)... Israel , May 5, 2015  Tikcro ... Company was approved to continue trading on OTCQB  ... OTCQB Marketplace allows for a continuous ... broker-dealers. Investors can have real-time quotes and market ... The OTCQB Marketplace includes U.S. and ...
Breaking Biology Technology:Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2Blueprint Medicines Announces Closing of Initial Public Offering 2Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2
... Cardica, Inc.,(Nasdaq: CRDC ) and Cook Medical ... the development of vascular closure,devices. Cook Medical will pay ... product for the closure device product line. "We ... to the next device in our vascular closure product ...
... Spectral Diagnostics Inc.,(TSX:SDI) today announced the market launch ... product for sepsis, in Germany through,A. Menarini Diagnostics ... Sepsis is the third most common cause of ... treatment of severe sepsis consumes,about one third of ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ), a biopharmaceutical ... candidates for the treatment,of cancer and infectious diseases, ... officer, is scheduled to present at the 2007 ... at 8:00 a.m.,Eastern Time. The conference takes place ...
Cached Biology Technology:Cardica and Cook Sign Agreement to Expand Cook Vascular Closure Device Product Family 2Cardica and Cook Sign Agreement to Expand Cook Vascular Closure Device Product Family 3Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany 2ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference 2
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... examining how the hormone jasmonate works to protect plants ... repressor of the jasmonate signaling pathway makes its way ... hope the recently published discovery will eventually help farmers ... harmful chemicals., "This is a small piece of a ...
... observations have revealed the first direct evidence of smoke ... tarnishing the ice with soot and making it more ... American Geophysical Union meeting this week, an Ohio State ... Infrared Pathfinder Satellite Observation (CALIPSO) satellite, which captured smoke ...
... 5, 2012Researchers at St. Michael,s hospital have identified 29 ... spread of kidney cancer. The discovery will help physicians ... and provide those patients with more intensive treatment and ... the most treatment-resistant malignancies and patients have dismal prognosis," ...
Cached Biology News:Biologists unlocking the secrets of plant defenses, 1 piece at a time 2Fire and ice: Wildfires darkening Greenland snowpack, increasing melting 2
...
... Apoptosis is an evolutionarily conserved form ... cellular process. The central component of ... enzymes called caspases. These enzymes participate ... triggered in response to pro-apoptotic signals and ...
... System provides optimized reagents and protocols for ... genes by insertion of group II introns. ... group II introns and utilizes a simple ... II intron for specific insertion into the ...
Mouse monoclonal antibody raised against a full length recombinant PPIL2. NCBI Entrez Gene ID = PPIL2...
Biology Products: